Newsletters

[GentiBio, Inc. (AllSci)] GentiBio, Inc. has received a USD 1.07 million NIH Phase II grant from the National Institute of Diabetes and Digestive and Kidney Diseases to advance an allogeneic, off-the-shelf engineered Treg therapy for newly diagnosed type 1 diabetes. q

[Blood] The authors discuss the history, preclinical studies, and successful translation of CD4+CD25+FoxP3+ Tregs in the context of allogeneic hematopoietic cell transplantation.

[Immunity] Researchers investigated whether melanocyte-intrinsic transcriptional program(s) underlie immune tolerance to mutations resulting from UV radiation exposure.

[Cell Host & Microbe] The authors investigated the therapeutic efficacy of two live biotherapeutic products, human Clostridia consortia 17-mix and 11-mix, by treating established colitis in murine models. Both LBPs exhibited therapeutic effects in T cell-mediated chronic colitis models induced by human microbiota and in pathobiont-driven gnotobiotic colitis models.

[Proceedings of the National Academy of Sciences of the United States of America] Using three complementary mouse models reflecting distinct causes of lupus-like disease, scientists show that disruption of the SLC15A4–TASL complex broadly prevents autoimmunity, including immune activation, pathogenic B cell responses, and autoantibody production.

[Signal Transduction and Targeted Therapy] Scientists review the induction strategies of Tregs, covering various aspects including antigenic stimulation, cytokine modulation, metabolic pathways, epigenetic regulation, drug induction, and engineered technology.

[Proceedings of the National Academy of Sciences of the United States of America] Researchers developed a therapy based on autologous red blood cells as tolerizing carriers of autoantigens and tested these in an open-label, dose-escalation, Phase Ib clinical trial with clinical, imaging, and mechanistic readouts.

[Cellular & Molecular Immunology] Investigators demonstrated that predominant Th1 inflammation manifests in both FOXP3V408M IPEX patients and FOXP3V408M knock-in mice and reveal that the mutation intrinsically impairs Treg-mediated control of Th1 inflammation.

[Circulation Research] Researchers analyzed human atherosclerosis single-cell RNA sequencing to map immune-vascular smooth muscle cell communication. They modeled atherosclerosis in adeno-associated virus–Pcsk9 or Apoe–/– mice.

[Children’s Hospital of Philadelphia] Dr. Andrei Thomas-Tikhonenko was awarded the $1 million V Foundation Pediatric All-Star Cancer Research Grant to develop a novel CAR T cell therapy for children with T cell acute lymphoblastic leukemia.

[Cell] Researchers developed PD-1-directed CAR T cells that selectively depleted pathogenic PD-1+ CD4 T cells and locally released IL-10.

[Medicus Pharma] Medicus Pharma announced that an abridged Clinical Study Report for SKNJCT-003 has been posted on ClinicalTrials.gov, providing public access to the clinical findings from the completed Phase II study. The study evaluated two dose levels of SkinJect® compared with a device-only microneedle comparator.